在抗肿瘤药物研发的复杂舞台上，Blenrep的故事宛如一出跌宕起伏的戏剧。曾几何时，这款靶向BCMA的抗体药物被视为GSK重返癌症领域的利器，然而，市场的残酷和临床试验的不确定性让它经历了一波三折的命运。对于许多人来说，Blenrep的退市似乎意味着它的终章，但就在GSK即将放弃时，新的希望又重新燃起。在临床试验DREAMM-7的中期分析显示出积极结果时，这款产品又重新回到了公众的视野中。

第15届医博会期间，同写意生物医药新基建链盟将举办ADC专场，邀请抗体/ADC研发端、生产端和供应链端的企业负责人与会深度交流，帮助行业优化和提升生物药创新生态链。

葛兰素史克称，Blenrep在与另一种名为BorDex的癌症疗法联合使用时，帮助那些骨髓瘤复发的患者们延长了寿命。这家英国制药巨头表示，后期临床试验 ...

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...

【葛兰素史克抗癌药物Blenrep显著降低死亡风险 有望重获监管批准】葛兰素史克公司表示，其血液癌症药物在与另一种癌症治疗药物联合使用 ...

One of the major stories in multiple myeloma in 2024 was the comeback of belantamab mafodotin (Blenrep) after it had been ...

Pharma titan GSK has announced that US regulators have accepted for review Blenrep combinations for the treatment of relapsed ...

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy, including overall survival in DREAMM-7 · If approved ...

GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration has accepted for review a Biologics License Application (BLA) ...